Zoetis is an animal health company specializing in the development and manufacturing of veterinary pharmaceuticals and vaccines for both livestock and companion animals. For FY2023, the company has...

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zoetis Inc., the world's largest provider of animal medicines, vaccines, and diagnostic products, is capitalizing on the growing trend of pet pampering. The company dominates the companion animal a...

Zoetis' (ZTS) revenues are expected to boost the pet care and livestock product sales in the quarters ahead. Disease outbreaks and potential supply challenges hurt prospects.

Kristin Peck, Zoetis CEO, joins 'Squawk on the Street' to discuss what the company's guidance was largely driven by, the most important aspect of Zoetis' business, and how new GLP-1 drugs could pla...

Zoetis Inc. (NYSE:ZTS ) Q22023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wett...

The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimate...

Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.

Zoetis (ZTS) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.32 per share. This compares to earnings of $1.20 per share a year ago.